These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 26982963)

  • 1. Treatment of Skin Ulcers Secondary to Sneddon Syndrome With Alprostadil (Prostaglandin E1).
    Collantes-Rodríguez C; Jiménez-Gallo D; Arjona-Aguilera C; Ossorio-García L; Linares-Barrios M
    JAMA Dermatol; 2016 Jun; 152(6):726-7. PubMed ID: 26982963
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful treatment of acquired reactive perforating collagenosis with doxycycline.
    Brinkmeier T; Schaller J; Herbst RA; Frosch PJ
    Acta Derm Venereol; 2002; 82(5):393-5. PubMed ID: 12430750
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of refractory ischemic skin ulcers in patients with Raynaud's phenomenon with PGE1 infusions.
    Langevitz P; Buskila D; Lee P; Urowitz MB
    J Rheumatol; 1989 Nov; 16(11):1433-5. PubMed ID: 2600942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Current therapy of Sneddon's syndrome].
    Wohlrab J; Fischer M; Marsch WC
    Dtsch Med Wochenschr; 2001 Jun; 126(25-26):758-60. PubMed ID: 11455669
    [No Abstract]   [Full Text] [Related]  

  • 5. The Sneddon syndrome.
    Aladdin Y; Hamadeh M; Butcher K
    Arch Neurol; 2008 Jun; 65(6):834-5. PubMed ID: 18541809
    [No Abstract]   [Full Text] [Related]  

  • 6. Sneddon's syndrome in a child.
    Gottlöber P; Bezold G; Schaer A; Stolz W; Friesecke I; Peter RU; Kerscher M
    Br J Dermatol; 2000 Feb; 142(2):374-6. PubMed ID: 10730781
    [No Abstract]   [Full Text] [Related]  

  • 7. Chronic infiltrates and persisting ulcerations on the arms and legs.
    von Stebut E; Wiest K; Braeuninger W
    Arch Dermatol; 2005 Jul; 141(7):897-902. PubMed ID: 16027309
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of ischemic ulcers of the lower limbs with alprostadil (prostaglandin E1).
    Tondi P; Gerardino L; Santoliquido A; Pola R; Gabrielli M; Papaleo P; Gasbarrini A; Pola P; Flore R
    Dermatol Surg; 2004 Aug; 30(8):1113-7. PubMed ID: 15274701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of complications of peripheral obstructive arterial disease with prostaglandin E1.
    Killion DD; Ambrus JL
    Angiology; 1987 Jul; 38(7):507-13. PubMed ID: 3619123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy for Sneddon syndrome to reduce the incidence of cerebrovascular complications.
    Narwutsch A; Wohlrab J; Sperfeld AD; Sunderkötter C
    J Dtsch Dermatol Ges; 2024 Jul; 22(7):947-954. PubMed ID: 38978420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sneddon's syndrome: a case report.
    Lahti J; Yu T; Burnett JW; Lutz L; LaMonte MP; Gunawardane R
    Cutis; 2001 Mar; 67(3):211-4, 220. PubMed ID: 11270293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Skin ulcerations due to CINCA syndrome and its successful treatment with prostaglandin E
    Brochhausen C; Babel M; Schmitt VH; Grevenstein D; Schreml S; Meyer-Scholten C; Klaus G
    Z Rheumatol; 2018 Sep; 77(7):633-636. PubMed ID: 30066026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous thrombolysis in Sneddon's syndrome.
    Sun J; Zhang F; Gao F; Wang J; Selim M; Lou M
    J Clin Neurosci; 2012 Feb; 19(2):326-8. PubMed ID: 22118882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter double blind controlled study of lipo-PGE1, PGE1 incorporated in lipid microspheres, in peripheral vascular disease secondary to connective tissue disorders.
    Mizushima Y; Shiokawa Y; Homma M; Kashiwazaki S; Ichikawa Y; Hashimoto H; Sakuma A
    J Rheumatol; 1987 Feb; 14(1):97-101. PubMed ID: 3553591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Not Available].
    Pobitzer K; Lautenschlager S
    Praxis (Bern 1994); 2016 Sep; 105(18):1108-9. PubMed ID: 27606922
    [No Abstract]   [Full Text] [Related]  

  • 16. Iontophoretic administration of prostaglandin E1 in peripheral arterial occlusive disease.
    Sakurai T; Yamamura K
    Ann Pharmacother; 2003 May; 37(5):747. PubMed ID: 12708957
    [No Abstract]   [Full Text] [Related]  

  • 17. Moyamoya in a patient with Sneddon's syndrome.
    Fierini F; Barilaro A; Giambene B; Carlucci G; Grandi V; Maio V; Pantoni L
    Clin Neurol Neurosurg; 2015 Feb; 129():34-6. PubMed ID: 25528372
    [No Abstract]   [Full Text] [Related]  

  • 18. [Sneddon syndrome presenting with dementia].
    Rodríguez Campello A; Roquer J; Munteis E; Gomis M; Pou A
    Neurologia; 2002; 17(7):394-5. PubMed ID: 12236963
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of prostaglandin E1 on collagen diseases with high levels of circulating immune complexes.
    Yoshikawa T; Suzuki H; Kato H; Yano S
    J Rheumatol; 1990 Nov; 17(11):1513-4. PubMed ID: 2273493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current diagnosis of Sneddon syndrome].
    Wohlrab J; Fischer M; Marsch WC
    Dtsch Med Wochenschr; 2001 Jun; 126(24):725-8. PubMed ID: 11446030
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.